Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HBB | P68871 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | PNP | P00491 | 3/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 8-Aminoguanine SCHEMBL21760 | 0.83 | KDM4E (0.60) | KDM4EALDH1A1LMNAGLAPMP22 | |
| SCHEMBL160586 | 0.76 | ALDH1A1 (0.53) | KDM4EALDH1A1LMNAGLAPMP22 | |
| SCHEMBL159447 | 0.76 | KDM4E (0.53) | KDM4EALDH1A1LMNAGLAPMP22 | |
| SCHEMBL843931 | 0.76 | LMNA (0.53) | KDM4EALDH1A1LMNAGLAPMP22 | |
| SCHEMBL2206472 | 0.76 | KDM4E (0.53) | KDM4EALDH1A1LMNAGLAPMP22 | |
| SCHEMBL6686385 | 0.76 | KDM4E (0.53) | KDM4EALDH1A1LMNAGLAPMP22 | |
| SCHEMBL158423 | 0.76 | KDM4E (0.53) | KDM4EALDH1A1LMNAGLAPMP22 | |
| SCHEMBL42761 | 0.76 | KDM4E (0.53) | KDM4EALDH1A1LMNAGLAPMP22 | |
| SCHEMBL9115 | 0.76 | KDM4E (0.53) | KDM4EALDH1A1LMNAGLAPMP22 | |
| SCHEMBL1270582 | 0.76 | KDM4E (0.49) | KDM4EALDH1A1LMNAGLAPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257360-A1 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | UNIV OKLAHOMA (US) | 2025-08-14 | — | — | US | claimed |
| CN-113151261-B | Antisense oligonucleotides as inhibitors of TGF-R signaling | 神经视觉医药有限公司 | 2025-06-17 | — | — | CN | claimed |
| CN-118931997-A | Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis | 上海飞腾医药科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| US-20240294924-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-09-05 | — | — | US | claimed |
| CN-117795071-A | Antisense oligonucleotides for preventing renal dysfunction caused by endothelial dysfunction through inhibition of ephrin-B2 | 马克斯·普朗克科学促进学会 | 2024-03-29 | — | — | CN | claimed |
| EP-4330397-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-03-06 | — | — | EP | claimed |
| WO-2023196944-A2 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2023-10-12 | — | — | WO | claimed |
| WO-2022263569-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-12-22 | — | — | WO | claimed |
| EP-4105328-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-12-21 | — | — | EP | claimed |
| US-20220143071-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | Neurovision Pharma GmbH (DE) | 2022-05-12 | — | — | US | claimed |
| US-20030194741-A1 | COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | CAPROTEC BIOANALYTICS GMBH (DE) | 2003-10-16 | — | — | US | claimed |
| EP-1295891-A1 | NUCLEOSIDE DERIVATIVES | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | claimed |
| US-20030054410-A1 | Combinatorial protecting group strategy for multifunctional molecules | CAPROTEC BIOANALYTICS GMBH (DE) | 2003-03-20 | — | — | US | claimed |
| US-6528639-B2 | Active ribozyme | RIBOZYME PHARMACEUTICALS, INC. | 2003-03-04 | — | — | US | claimed |
| US-5891684-A | RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-04-06 | — | — | US | claimed |
| EP-0898575-A2 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KÖSTER, Hubert (US) | 1999-03-03 | — | — | EP | claimed |
| WO-1997041139-A2 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KOESTER HUBERT (US) | 1997-11-06 | — | — | WO | claimed |
| US-5665541-A | Formation of triple helix complexes for the detection of double stranded DNA sequences using oligomers which comprise an 8-modified purine base | THE JOHNS HOPKINS UNIVERSITY (US) | 1997-09-09 | — | — | US | claimed |
| EP-0672171-A1 | FORMATION OF TRIPLE HELIX COMPLEXES OF DOUBLE STRANDED DNA USING NUCLEOSIDE OLIGOMERS WHICH COMPRISE PURINE BASE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 1995-09-20 | — | — | EP | claimed |
| WO-1993005180-A1 | FORMATION OF TRIPLE HELIX COMPLEXES OF DOUBLE STRANDED DNA USING NUCLEOSIDE OLIGOMERS WHICH COMPRISE PURINE BASE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 1993-03-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143071-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | TGFBR1, TGFBR2, TGFB1 | KDM4E 4454/4885ALDH1A1 4264/4885LMNA 920/4885 |
| US-20030194741-A1 | COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | ADAR, RNMT, ATIC | KDM4E 3956/4885ALDH1A1 4111/4885LMNA 2407/4885 |
| US-20030054410-A1 | Combinatorial protecting group strategy for multifunctional molecules | ADAR, RNMT, RRM1 | KDM4E 4038/4885ALDH1A1 3683/4885LMNA 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.